Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Veracyte (VCYT) over the last 14 years, with Dec 2024 value amounting to $24.1 million.

  • Veracyte's Net Income towards Common Stockholders rose 26.33% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.3 million, marking a year-over-year increase of 426.92%. This contributed to the annual value of $24.1 million for FY2024, which is 132.44% up from last year.
  • According to the latest figures from FY2024, Veracyte's Net Income towards Common Stockholders is $24.1 million, which was up 132.44% from -$74.4 million recorded in FY2023.
  • Veracyte's Net Income towards Common Stockholders' 5-year high stood at $24.1 million during FY2024, with a 5-year trough of -$75.5 million in FY2021.
  • For the 3-year period, Veracyte's Net Income towards Common Stockholders averaged around -$28.9 million, with its median value being -$36.6 million (2022).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first slumped by 177.08% in 2020, then surged by 132.44% in 2024.
  • Yearly analysis of 5 years shows Veracyte's Net Income towards Common Stockholders stood at -$34.9 million in 2020, then slumped by 116.42% to -$75.5 million in 2021, then spiked by 51.61% to -$36.6 million in 2022, then plummeted by 103.51% to -$74.4 million in 2023, then soared by 132.44% to $24.1 million in 2024.